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Summary Cells of a patient with Turcot's syndrome and of her parents were evaluated for the presence of
molecular alterations in the p53 and the Ki-ras gene. Deletions on chromosome 17p, overexpression and point
mutations of the p53 gene as well as mutations of the Ki-ras gene were detected in primary and metastatic
tumour but not in the germline of the patient nor in her parents.
Colorectal cancer is one of the most common malignancies in
man, and environmental as well as hereditary factors are
involved in the carcinogenic process. A small subset of colo-
rectal cancers (<1%) develops in patients with one of the
polyposis coli syndromes: familial adenomatous polyposis
(FAP), Gardner's syndrome, and Turcot's syndrome (Lynch
et al., 1991).
Turcot's syndrome, the association of intestinal polyposis
with neuroepithelial brain tumours such as glioma, glioblas-
toma and medulloblastoma, was first described by Crail in
1949 (Crail, 1949), and later by Turcot et al. (1959). So far,
some 30 cases have been reported in the literature, but there
is no information on molecular alterations involved in the
development and progression of the disease.
Sporadic mutations in the p53 tumour suppressor gene are
the most common genetic alterations observed in human
malignancies (Levine et al., 1991), and occur in approx-
imately 70% of colorectal cancers (Hollstein et al., 1991).
Recently, germline mutations of the p53 gene have been
described in patients with Li-Fraumeni syndrome and other
hereditary forms of cancer (Malkin et al., 1990, 1992;
Srivasta et al., 1990; Toguchida et al., 1992).
To determine the role of p53 and other oncogenes and
tumour suppressor genes in Turcot's syndrome, we studied
tissues derived from a 15-year-old patient with polyposis coli,
metastasising colorectal cancer, and malignant astrocytoma
as well as from her parents.
Materials and methods
Case report
A 15-year-old girl was admitted with a history of abdominal
cramps and rectal bleeding. Colonoscopy detected 10-20
adenomatous sigmoid polyps of 2 to 5 cm diameter and ten
further polyps scattered over the whole range of the colon.
There was no family history of polyposis coli, and on endo-
scopy, neither the patient's brother nor her parents had rectal
or colonic polyps. The polyps were endoscopically excised
and one of the sigmoid polyps was found to contain adeno-
carcinoma. A left hemicolectomy of a Dukes Cl colorectal
cancer was performed. Eight months later, ultrasound exam-
ination of the liver showed three metastases in the left lobe,
leading to a left hemihepatectomy. Two months later, a
cranial CT scan detected a 5 cm right lateral mass. A crani-
otomy was performed and the tumour partially removed.
Histological evaluation revealed grade III astrocytoma. A
few weeks later the patient developed histologically con-
firmed skin metastases of the adenocarcinoma and finally
died of the sequelae of her brain tumour.
Tissues
Material from the hemicolectomy was available as paraffin
embedded block only. Tissues from the hemihepatectomy,
the craniotomy, and the skin-metastasectomy were frozen
with liquid nitrogen and stored at -80°C. Figure 1 shows
representative photomicrographs of the benign and malig-
nant tissues that were used for immunohistochemical and
molecular evaluation in this study.
Ras mutation analysis
PCR-amplified fragments of the Ki-ras gene were probed on
slot-blots with labelled mutation-specific oligomers as des-
cribed previously (Rochlitz et al., 1989).
VNTR-amplification
To detect loss of heterozygozity (LOH) on chromosome 17p,
we used PCR-directed amplification of a VNTR region on
the pYNZ22 locus as described by Horn et al. (1989).
Sequencing ofp53
Exons 4-9 of the p53 gene were PCR-amplified and sequenc-
ed as described (Baker et al., 1989).
APAAP
Immunohistochemical staining of the p53 protein was per-
formed using the murine monoclonal antibody PAbl 801
(Dianova, Hamburg, Germany) as described (Cordell et al.,
1984).
Differential PCR
To measure the expression of the p53 gene we used differ-
ential PCR as described by others and ourselves (Frye et al.,
1989; Neubauer et al., 1990; Noonan et al., 1990).
Results
The lymph node, the skin and the liver metastasis of the
patient's colon carcinoma carried a glycine to alanine muta-
tion in codon 12 of the Ki-ras gene, while the primary colon
carcinoma as well as the astrocytoma and all the normal
tissues harboured only the wild type allele of the Ki-ras gene
(Figure 2).
To test for LOH within chromosome 17p, the site of the
p53 gene, we analysed a VNTR (variable number of tandem
repeats) length polymorphism at the pYNZ22 locus. Figure 3
shows that the patient is heterozygous for a paternal 400 bp
and a maternal 300 bp fragment. A heterozygous allelic loss
of the paternal pYNZ22 allele is demonstrated in the liver
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Figure 1 Microphotographs of benign and malignant tissues from a patient with Turcot's syndrome. a, normal colonic mucosa; b,
adenomatous polyp; c, normal lymph follicle of colonic mucosa; d, primary sigmoid cancer; e, lymph node metastasis of sigmoid
carcinoma; f, liver metastasis of sigmoid carcinoma; g, skin metastasis of sigmoid carcinoma; h, grade III astrocytoma.MOLECULAR ALTERATIONS IN TURCOT'S SYNDROME 521
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Figure 2 Ki-ras mutation analysis of a patient with Turcot's syndrome and her parents. Three different metastases of a colon
carcinoma carry the same glycine to alanine mutation in codon 12 of the Ki-ras gene, while the primary colon carcinoma as well as
the astrocytoma and all the normal tissues harbour only the wild type (WT) allele of the Ki-ras gene. In addition, a known glycine
to asparagine mutation is shown in nude mouse tumour CR104 (Rochlitz et al., 1993). The DNA from the colon mucosa (Muc)
and the adenoma (Ad) was extracted from paraffin and was degraded to an extent that did not allow amplification and detection of
the WT sequence in that experiment. F = father; M = mother; PB = peripheral blood; Muc = normal colon mucosa; Ad =
adenoma; CC = colon cancer; LN Met = lymph node metastasis; Liv Met = liver metastasis; Sk Met = skin metastasis; Ast = astro-
cytoma; CR104 = nude mouse xenograft of a colon carcinoma; H20 = water control; Gly = glycine; WT = wild type; Ala=
alanine; Asp = asparagine.
and skin metastases of the colon cancer but not in the
astrocytoma. Sequencing of the p53 gene revealed an arginine
to histidine mutation in codon 175 in the liver and the skin
metastasis of the CRC (Figure 4) and an arginine to histidine
mutation in codon 273 in the astrocytoma. There was no
mutation of the p53 gene in the lymphocytes of the patient or
her parents.
Immunocytochemistry confirmed the results of p53 se-
quencing: intense nuclear staining with the anti-p53 antibody
PAbl801 was observed in the skin and the liver metastasis of
the CRC whereas the astrocytoma showed weak cytoplasmic
staining. By use of differential PCR the p53 mRNA expression
(relative to normal colonic mucosa) of the liver metastasis,
the skin metastasis, and the astrocytoma were determined to
be 1.5, 2.4 and 1.8, respectively (data not shown).
Discussion
The case presented here are that of a 15-year-old girl with
polyposis coli, colonic carcinoma metastasising to lymph
nodes, the liver and the skin, and a high grade astrocytoma,
representing a Turcot's syndrome, type III in the Lewis
classification system (Lewis et al., 1983).
In the molecular analysis of this patient's tumours we
focused our attention to chromosome 17p and the p53
tumour suppressor gene for two reasons: first, p53 is the
most frequently altered gene in both colorectal cancer and
brain tumours (Vogelstein et al., 1988; Hollstein et al., 1991;
von Deimling et al., 1992). Second, p53 is one of the genes
that may predispose to the development of cancer, and
reports on p53 germline mutations in several hereditary
cancer syndromes have been published recently (Malkin et
al., 1990, 1992; Srivasta et al., 1990; Santibanez-Koref et al.,
1991; Toguchida et al., 1992).
Our findings of a codon 175 point mutation of the p53
gene in the skin and the liver metastasis of a sigmoid car-
cinoma and of a codon 273 mutation in the astrocytoma of
our patient demonstrate that the p53 gene played a role in
the carcinogenic process. In addition, deletions on chromo-
some 17p, the location of the p53 gene, were present in both
the skin and the liver metastasis of the sigmoid carcinoma
but not in the astrocytoma. Similarly, increased protein and
mRNA expression of p53 was shown in all the malignant
tissues of the patient. Lymphocytes from the patient and her
parents were also evaluated for p53 mutations but found to
contain solely the wild type sequence of the gene. This argues
strongly against a role of p53 as a cancer predisposition gene
in this case of Turcot's syndrome.
Alterations of other genes involved in tumour development
and progression were also examined. The fact that a Ki-ras
mutation was detected in three different metastases of the
sigmoid carcinoma but not in a colonic adenoma, the sig-
moid primary tumour or in the astrocytoma, suggests that
this ras mutation might have occurred in a single cell, late in
the development of the primary colon cancer, enabling this
cell to metastasise to different sites.
In addition, overexpression of the c-myc oncogene, the
nm23 'metastasis suppressor gene', and of the MDRl gene
was detected in some of the malignant tissues (data not
shown) and underlines that the same genetic events that drive
the carcinogenic process in diverse human sporadic malig-
nancies were involved in this rare hereditary disease.
Germline alterations different from those analysed in this
study must be responsible for the predisposition to malig-
nancy in this individual patient. In the light of the well
F M522 C.F. ROCHLITZ et al.
Figure 3 Amplification of the polymorphic locus pYNZ22 on chromosome 17p by PCR. A heterozygous allelic loss of the
paternal pYNZ22 allele is demonstrated in the liver (LM) and skin (SM) metastasis of the sigmoid carcinoma. Abbreviations see
legend to Figure 2.
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Figure 4 Demonstration of an arginine to histidine (CGC-CAC) mutation in codon 175 of the p53 gene in the skin metastasis of
the colon carcinoma of a patient with Turcot's syndrome. M = skin metastasis; N = normal tissue.
known importance of the DCC, MCC and APC genes in remain to be examined in patients with Turcot's syndrome.
colorectal carcinoma and familiar adenomatous polyposis This work was supported by the Wilhelm Sander-Stiftung, Neustadt
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